Burlingame, CA, United States of America

Scott E Lazerwith

USPTO Granted Patents = 55 

 

 

Average Co-Inventor Count = 7.8

ph-index = 12

Forward Citations = 419(Granted Patents)

Forward Citations (Not Self Cited) = 337(Oct 12, 2025)


Location History:

  • Foster City, CA (US) (2012)
  • San Francisco, CA (US) (2011 - 2024)
  • Burlingame, CA (US) (2017 - 2024)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
55 patents (USPTO):

Title: The Innovative Contributions of Scott E. Lazerwith

Introduction

Scott E. Lazerwith, based in Burlingame, California, is a prominent inventor recognized for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 49 patents, Lazerwith has made substantial strides in the development of therapeutic compounds aimed at combating various viral infections.

Latest Patents

Among his latest innovations, Lazerwith has developed phospholipid compounds, which encompass pharmaceutical compositions with potential applications in treating viral infections. This patent outlines the methodologies for synthesizing and utilizing these compounds to address infections caused by numerous viral families, including paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae.

Another recent patent focuses on substituted pyrrolizine compounds, which are designed to inhibit hepatitis B virus (HBV) replication. The application details both the pharmaceutical compositions and the production methods for these compounds, highlighting their importance in antiviral research and therapy.

Career Highlights

Scott E. Lazerwith has held positions at several noteworthy companies, including Gilead Sciences, Inc. and Gilead Pharmasset LLC. His experience in these leading pharmaceutical firms has equipped him with the expertise to innovate and drive research forward in the quest for effective antiviral treatments.

Collaborations

During his career, Lazerwith has had the opportunity to collaborate with other accomplished professionals in the field, including Hyung-Jung Pyun and William John Watkins. These partnerships reflect a shared commitment to advancing research in pharmaceuticals and enhancing therapeutic applications for global health initiatives.

Conclusion

Scott E. Lazerwith continues to be a vital contributor to the realm of pharmaceutical inventions, with a strong emphasis on innovation in antiviral therapies. His extensive patent portfolio not only signifies his dedication to scientific advancement but also underscores the potential impact of his work in improving public health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…